Friday, 13 Sep 2019

You are here

Preventing Hep B Reactivation Due to Immunosuppressive Drug Treatments

Reactivation of hepatitis B virus infection can have devastating consequences, especially amongst those patients receiving immunosuppressive therapy.

HBV reactivation, with hospitalization or fatal outcomes have been described in patients receiving rituximab, TNF inhibitors (infliximab, etanercept, adalimumab), abatacept, tocilizumab, azathioprine and prednisone to name a few. Interestingly, there have been no or few reports of HBV reactivation in rheumatic patients receiving methotrexate, anakinra or tofacitinib. Importantly, reactivation can occur in patients with RA, Still’s disease, psoriatic disease, colitis and spondylitis, cancer and transplantation patients. Those affected are unified by the certain factors that tip the risk in favor of reactivation. There are ways to identify those at high and low risk for reactivation.

Perrillo et al reviews strategies to prevent HBV reactivation in a recent JAMA article. They state that patients with active HBV infection who are HBsAg positive are at greatest risk for reactivation. HBsAg+ patients who are receiving chemotherapy have a 40% risk of HBV reactivation with a subsequent risk of liver failure (13%) or death (16%).   

Patients who have resolved HBV infection (HBsAg negative and HBcAb positive) are at a much lower risk of HBV reactivation. In my review of the literature, reactivation was seen in < 1% of patients on TNF inhibitors with resolved HBV infection. Perillo estimates the risk w/ TNF inhibitors to be 0-5% and 3-41% for patients receiving R-CHOP (with RTX rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone). Hence, the depth of immunosuppression (augmented by cytotoxics, radiation, high dose steroids) may substantially augment the low risk that accompanies a resolved HBV serologic profile.

Current recommendations include:

  1. All patients starting immunosuppressive therapy (biologics, DMARDs, high dose steroids, chemotherapy) should be screened for active, resolved/occult HBV (and hepatitis C) infection.

  2. Patients who are HBsAg+ should avoid immunosuppressives, but if required, such patients should receive antiviral prophylaxis (e.g., lamivudine, entecavir,  tenofovir, etc). Prophylaxis should also be given to selected resolved HBV patients who are HBsAg negative and anti-HBc–positive who will receive B-cell–depleting agents or other highly aggressive chemotherapy. Prophylaxis is not 100% effective and patients should have their hepatic enzymes and HBV DNA levels monitored regularly and continued for up to 12 months after suspension of immunosuppression.

Add new comment

More Like This

Rise in Fatty Liver Disease Linked to Obesity and Diabetes

Gut has published population results from NHANES population study showing that the prevalence of fatty liver disease is rising in the US and is driven by obesity and diabetes.

Employed Physicians Outnumber Self-Employed

For the first time in the United States, employed physicians outnumber self-employed physicians, according to a newly updated study on physician practice arrangements by the American Medical Association (AMA). This milestone marks the continuation of a long-term trend that has slowly shifted the distribution of physicians away from ownership of private practices.

 

Dr. Harold E. Paulus (1929-2019)

Dr. Harold “Hal” Paulus lives in the annals of Rheumatology as a major contributor, mentor, researcher and clinical trialist. He passed away last week, one day after his 89th birthday. I met Dr. Paulus as a fellow in 1985, when he easily included me in his discussions and research on rheumatoid arthritis. I admired his easy demeanor, wry humor and every man character. Most remark on his calm recessive and kind personality that was complemented by a body of work that was large, impactful and usually at the cutting edge. Many of Dr. Paulus’ colleagues and friends have contributed their testimonies and fond memories of this great man.

RheumNowLive On Demand: The History of Steroids - Dr. Eric Matteson

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

Mourning the Loss of NIAMS Director Stephen Katz, MD, PhD

The following tribute to the late Dr. Steven Katz appeared on the NIH website.